Provided By GlobeNewswire
Last update: Apr 9, 2025
– Clinical and preclinical data supporting dosing profile and tolerability for ABI-5366, a novel long-acting helicase-primase inhibitor candidate, featured in two poster presentations –
Read more at globenewswire.comNASDAQ:ASMB (5/30/2025, 8:00:01 PM)
14.15
-0.05 (-0.35%)
Find more stocks in the Stock Screener